Desmoplastic Small Round Cell Tumor (DSRCT) Research Fund
Desmoplastic Small Round Cell Tumour (DSRCT) is a rare and aggressive type of soft tissue sarcoma that affects young people, particularly male adolescents and young adults. Survival ranges from just four to 21 months and only 15% of people survive five years. This must change.
BC Cancer Clinician Scientist Dr. Torsten Nielsen and a team of experts are seeking to develop more effective treatments for people facing DSRCT. To achieve this goal, they have identified two critical priorities:
- Develop a lab model of DSRCT to test the effectiveness of new drugs in comparison to standard chemotherapy; and
- Create a comprehensive DSRCT tissue and biological resource to study patient outcomes, genomic profiles and lay the groundwork for drug testing and clinical trials.
This will lead to the first comprehensive epigenomic profile of DSRCT. Together, these priorities will fuel vital research, resulting in new, more effective therapies for metastatic DSRCT. Generous support for this fund will ensure the success of Dr. Nielsen’s lab now and for years to come.